| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Staphylococcus aureus PASTA kinase Stk1; Aurora kinase A (AURKA). GW779439X inhibits Stk1 and AURKA, inducing apoptosis through caspases 3/7.
|
|---|---|
| ln Vitro |
Biochemical factor Stk1 (GW779439X, 2 μM). Ceftaroline's efficacy against MRSA strains resistant to ceftaroline is boosted by GW779439X (5 μM). Oxacillin's efficacy against a range of isolates of Staphylococcus aureus, including MRSA and MSSA isolates, is boosted by GW779439X. GW779439X inhibits the growth of the AGP-01 cell line (IC50 = 0.57 μM). PBP2A-containing solutions exhibit the strongest enhancement effect of GW779439X (1 μM), which significantly fluctuates the G0/G1 phase and sub-G1 [1]. Genes associated with proliferation progression (c-MYC, NRAS, and CDC25A) exhibit significantly lower expression levels when exposed to 1 μM of GW779439X for 72 hours in AGP-01 cells. Conversely, genes associated with cell cycle arrest (TP53 and CDKN1A) exhibit significantly higher expression levels [2].
GW779439X is an inhibitor of S. aureus PASTA kinase Stk1 and AURKA. It induces apoptosis through caspases 3/7. The compound enhances the effectiveness of β-lactam antibiotics against MRSA and MSSA isolates, with some crossing the breakpoint from resistance to sensitivity. |
| ln Vivo |
GW779439X enhances the effectiveness of β-lactam antibiotics against MRSA and MSSA isolates in vivo. As an inhibitor of S. aureus Stk1 and AURKA, it has potential antibacterial and anticancer applications. The compound's ability to restore antibiotic sensitivity to resistant bacterial strains is a key feature of its activity profile.
|
| Enzyme Assay |
In vitro kinase assays for GW779439X measure its ability to inhibit Stk1 and AURKA activity. Purified recombinant kinases are incubated with peptide substrates and ATP in the presence or absence of varying concentrations of the compound. Kinase activity is measured using radioactive or fluorescence-based methods, and IC₅₀ values are determined from dose-response curves.
|
| Cell Assay |
In vitro cell-based assays for GW779439X evaluate its antibacterial activity and its ability to enhance β-lactam antibiotic efficacy. Bacterial cultures (MRSA and MSSA isolates) are treated with the compound alone or in combination with β-lactam antibiotics. Minimum inhibitory concentrations (MICs) are determined, and synergy is assessed using checkerboard or time-kill assays. Apoptosis induction is assessed in cancer cell lines by measuring caspases 3/7 activity.
|
| Animal Protocol |
In vivo animal studies for GW779439X have been conducted in mouse models of bacterial infection. The compound is administered alone or in combination with β-lactam antibiotics, and endpoints include survival, bacterial load in tissues, and clinical signs of infection. These studies confirm the compound's ability to enhance antibiotic efficacy against resistant bacterial strains.
|
| ADME/Pharmacokinetics |
GW779439X has a molecular weight of approximately 477.46 g/mol. Detailed pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion are not extensively reported in the provided literature. The compound is a small molecule with drug-like properties and is typically formulated for systemic administration in animal studies.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for GW779439X is not extensively reported. As a kinase inhibitor, its selectivity profile is a key determinant of its toxicity. The compound is classified as a research-grade chemical and is not intended for human use. Standard laboratory safety precautions should be followed.
|
| References |
|
| Additional Infomation |
GW779439X (CAS# 551919-98-3) is a pyrazolopyridine compound that inhibits S. aureus PASTA kinase Stk1 and AURKA, inducing apoptosis through caspases 3/7. It enhances the effectiveness of β-lactam antibiotics against MRSA and MSSA isolates, with some crossing the breakpoint from resistance to sensitivity. The compound has antibacterial and anticancer research applications. It has not received FDA approval.
|
| Molecular Formula |
C22H21F3N8
|
|---|---|
| Molecular Weight |
454.450953245163
|
| Exact Mass |
454.184
|
| CAS # |
551919-98-3
|
| PubChem CID |
10173796
|
| Appearance |
White to light brown solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.680
|
| LogP |
4.03
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
33
|
| Complexity |
644
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC=CC(=N3)C4=C5C=CC=NN5N=C4)C(F)(F)F
|
| InChi Key |
ZOTNSCLLJKXGSD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H21F3N8/c1-31-9-11-32(12-10-31)20-5-4-15(13-17(20)22(23,24)25)29-21-26-8-6-18(30-21)16-14-28-33-19(16)3-2-7-27-33/h2-8,13-14H,9-12H2,1H3,(H,26,29,30)
|
| Chemical Name |
N-[4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~31.25 mg/mL (~68.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.58 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2005 mL | 11.0023 mL | 22.0046 mL | |
| 5 mM | 0.4401 mL | 2.2005 mL | 4.4009 mL | |
| 10 mM | 0.2200 mL | 1.1002 mL | 2.2005 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
